Capturing Value: What business models are next for the biopharma world?
September 23-25, 2008
New York Marriott Downtown • New York City
|
|
|
|
|
Individual
Registration: $1995
Company Registration: $1795 3 or more attendees, each
|
|
|
|
|
|
|
It’s THE MOST senior level case studies for dealmaking and strategy available in the industry.
Windhover's 18th Annual Pharmaceutical Strategic Alliances is simply where you will meet the most important people in the business.
DON'T MISS
these top-level speakers!
Martin Mackay
President, Pfizer Global Research & Development
Adam Schechter
President of US Human Health, Merck & Co.
Steven Paul MD
President, Lilly Research Laboratories
Paul Stoffels PhD
Chairman, Worldwide R&D, Johnson &
Johnson
Even the optimists in the pharma and biotech worlds don’t see much future for business-models-as-usual. They may not agree on the model – but they agree that what we’ve got isn’t right. The 2008 PSA conference focuses on what’s next for the broader biopharma worlds – models that break down the walls between Big Pharma, biotech and spec pharma pipelines, and open up the financing opportunities to a much broader investment audience. PSA looks at these innovative ways of developing medicines and capturing value.
While Big Pharma struggles to think small, biotechs wrestle with how to get big – in value – without all that infrastructure.
So while Big Pharma tries to recreate biotech creativity, spins off research and products, cuts costs … biotech experiments with ways of dispensing with vertical interpretation. Is ripping apart the value chain the next step for both? As they do so, traditional pharmaceuticals will be at the very heart of the activity. You can follow – even shape – the actions at the industry’s most important strategy meeting: Pharmaceutical Strategic Alliances.
Maximize your strategic alliance opportunities by hearing CEOs, senior R&D and senior business development executives share lessons learned, practical advice and strategies on how to build your R&D pipeline – both internally and externally. Take away the newest strategies and tactics that you can apply to your company’s dealmaking efforts immediately!
And this September, PSA offers you an unbeatable line-up of Big Pharma and biotech speakers to forecast trends and analyze changes in alliances and M&A. You’ll hear from, and be able to quiz, top industry executives and dealmakers.
PSA gathers top thinkers to grapple with the fundamental challenges facing biotech and pharma – equipping dealmakers like you with the insights, information and practical advice you'll need to strike successful deals. This program will sell out so register early. Space is limited, so register today!
BEYOND THE BASICS! PSA attracts THE most strategic level speakers and audience. Past speakers include:
|
Richard Clark
CEO
Merck & Co.
Fred Hassan
CEO
Schering-Plough Corp.
Sidney Taurel
CEO
Eli Lilly and Company
Dr. Peter S. Kim
President
Merck Research Laboratories
|
Elliott Sigal, MD, PhD
EVP, CSO & President R&D
Bristol-Myers Squibb
Thomas Koestler, PhD
EVP, Schering-Plough
President, Schering-Plough Research Institute
Dr. Lee Babiss
Global Head of Pharma Research
Roche
Steven Marc Paul, M.D.
EVP of Science and Technology and
President of the Lilly Research Laboratories
Eli Lilly and Co.
|
And as always, you’ll be able to network and exchange ideas with an elite group of your peers, your colleagues, your partners and your competitors.
Pharmaceutical Strategic Alliances is going to explore the different strategies of externalization, from the podium and in the hallways, in a depth you will experience at no other conference because we have the speakers and the attendees who set the strategies.
By attending PSA, you can:
"Definitely worthwhile. Speakers focused on topics and insights, not on company promotion."
"Good opportunity to listen to various industry viewpoints regarding the state of pharmaceutical partnering process and outcomes."
"For a first time attendee I found the meeting extremely well-planned and informative."
"Excellent topic coverage, as well as representation of speakers."
"Interesting, relevant topics for the most part and good networking opportunities."
"I attend every year. The content is always engaging."
"One of the 'most attended' conferences, as always."
"The entire agenda is well thought-out and covers several very pertinent topics."
"Great chance to network with leading business development professionals in the industry and share collaboration ideas."
"One of the conferences that I learn something of value."
"A good review of what is going on at the pharma and biotech industries with a brilliant strategic analysis. Excellent selection of speakers and particiapants at the round table discussions."
"I appreciate Windhover conferences. Your organization is one of the few that is trying to understand the pharma/biotech industry in a strategic context."
"Overall, I was pleasantly surprised, it was an excellent meeting and exceeded my expectations because of the quality of attendees."
"It was very good, the presentations and networking opportunities were excellent."